Information Provided By:
Fly News Breaks for March 8, 2019
HRTX, PCRX
Mar 8, 2019 | 06:59 EDT
Stifel analyst Derek Archila lowered his price target on Pacira (PCRX) shares to $33 and reiterated a Sell rating on the stock, stating that the company's 22% year-over-year growth guidance for Exparel "is no lay-up" and he sees meaningful competitive pressure coming from Heron Therapeutics' (HRTX) HTX-011 and its expected positive news flow ahead of launch. While MyoScience's Iovera seems like it will fit very well within Pacira's current sales infrastructure, the acquisition of MyoScience "was certainly not the deal investors were looking for," added Archila.
News For PCRX;HRTX From the Last 2 Days
There are no results for your query PCRX;HRTX